Cutaneous Mycosis is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Cutaneous Mycosis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Cutaneous Mycosis compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cutaneous Mycosis overview
Cutaneous mycoses are a group of superficial fungal infections that affect the skin, hair, and nails. They are also known as superficial mycoses. They are confined to the outer layers of the skin, hair, or nails. They rarely invade deeper tissues or viscera, and do not induce a cellular response from the host. Most cutaneous mycoses are caused by dermatophytes, a group of filamentous fungi that colonize and infect keratinized tissues, including the outermost layer of skin.
For a complete picture of PTSR and LoA scores for drugs in Cutaneous Mycosis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
